Harpoon Therapeutics, Inc. announced that the US FDA has granted Orphan Drug Designation for HPN328, a delta like ligand 3- targeting TriTAC®, for the treatment of SCLC.
[Harpoon Therapeutics, Inc.]
6445212
nan
items
1
apa
0
default
asc
1
172730
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
